gavel

Roche sues Intas Pharma over patent dispute in India

pharmafile | April 18, 2016 | News story | Medical Communications, Sales and Marketing |  India, Roche, anaemia, chronic kidney, intas, intas pharmaceuticals, patent 

Roche Pharmaceuticals is suing Indian-based Intas Pharmaceuticals, alleging that the company has infringed upon its patent rights to anaemia drug, Mircera, in the country.

Mircera is an injectable drug used to treat patients with anaemia in chronic-kidney related conditions. It accounts for up to $500 million in global sales for the Swiss pharmaceutical firm.

Speaking to the Economic Times in India, Intas issued a statement claiming that they “also have strong grounds for invalidation of the enforced statement. Intas has launched its own product under the brand name Erypeg at a lower price to Roche’s Mircera, at the same dosage.

Advertisement

This is not the first time that Roche has brought proceedings against Intas in a patent dispute. In 2013, a court ruled in favour of the latter in a dispute related to Roche’s non-small cell lung cancer treatment, Tarceva (erlotinib hydrochloride).

According to the Economics Times, Roche has sought an injunction order against the Erypeg brand, but no decision has yet been taken.

Sean Murray

Related Content

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

blood_test

Roche candidate shows early promise for treating haemophilia A

Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Roche advances treatment for Parkinson’s disease

Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …

The Gateway to Local Adoption Series

Latest content